Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Research & Development (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Research & Development for 15 consecutive years, with $29000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 70.1% year-over-year to $29000.0, compared with a TTM value of $280000.0 through Sep 2025, down 3.11%, and an annual FY2024 reading of $307000.0, up 448.21% over the prior year.
  • Research & Development was $29000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $107000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $2.4 million in Q1 2021 and bottomed at $3000.0 in Q1 2024.
  • Average Research & Development over 5 years is $476777.8, with a median of $102000.0 recorded in 2024.
  • The sharpest move saw Research & Development plummeted 99.72% in 2023, then soared 3033.33% in 2025.
  • Year by year, Research & Development stood at $1.2 million in 2021, then tumbled by 90.58% to $117000.0 in 2022, then tumbled by 72.65% to $32000.0 in 2023, then soared by 56.25% to $50000.0 in 2024, then crashed by 42.0% to $29000.0 in 2025.
  • Business Quant data shows Research & Development for FENC at $29000.0 in Q3 2025, $107000.0 in Q2 2025, and $94000.0 in Q1 2025.